首页> Breast cancer research and treatment> A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer.

A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer.

导出 OA

翻译打印收藏纠错

第一作者： Christos,Vaklavas

第一单位： Huntsman Cancer Institute of the University of Utah, 2000 Circle of Hope, RS2509, Salt Lake, UT, 84112, USA. christos.vaklavas@hci.utah.edu.;University of Alabama at Birmingham, Birmingham, AL, USA. christos.vaklavas@hci.utah.edu.

作者： Christos,Vaklavas ^[1] ; Erica M,Stringer-Reasor ^[2] ; Ahmed M,Elkhanany ^[2] ; Kevin J,Ryan ^[2] ; Yufeng,Li ^[2] ; Charles P,Theuer ^[3] ; Edward P,Acosta ^[2] ; Shi,Wei ^[2] ; Eddy S,Yang ^[2] ; William E,Grizzle ^[2] ; Andres,Forero-Torres ^[2]

作者单位： Huntsman Cancer Institute of the University of Utah, 2000 Circle of Hope, RS2509, Salt Lake, UT, 84112, USA. christos.vaklavas@hci.utah.edu.;University of Alabama at Birmingham, Birmingham, AL, USA. christos.vaklavas@hci.utah.edu. ^[1] University of Alabama at Birmingham, Birmingham, AL, USA. ^[2] TRACON Pharmaceuticals, San Diego, CA, USA. ^[3]

关键词 Angiogenesis inhibitors Breast cancer Carotuximab Everolimus Letrozole Neoadjuvant therapy

医学主题词人类(Humans);女(雌)性(Female);乳腺肿瘤(Breast Neoplasms);组织分布(Tissue Distribution);抗体, 单克隆(Antibodies, Monoclonal);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols)

DOI 10.1007/s10549-023-06864-9

PMID 36735117

发布时间 2026-01-27

基金项目

P30 CA013148/CA/NCI NIH HHS/United States UG1 CA233330/CA/NCI NIH HHS/United States

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交